| Israeli PM says he has prostrate cancer
Israeli Prime Minister Ehud Olmert on Monday said that he has been diagnosed with prostate cancer, but the disease is not life threatening and he will ''continue to perform his duties''.
At a hastily convened press conference, Olmert, 62, said the condition had been disclosed to him earlier this month during a routine medical check up following his visit to Russia and that he had ''full chances of recovery''.
The prime minister said that the tumor was microscopic with no metastasies.
''I will be able to fulfill duties fully before my treatment and hours afterward,'' Olmert said adding, ''My doctors told me that I have full chances of recovery.''
One of Olmert's doctors, Shlomo Segev, said the tumor ''is restricted to the prostate and is of no danger to him.'' The prime minister had a biopsy on October 19 and got the results a week later, Segev said.
Olmert upbeat after cancer diagnosis
JERUSALEM—Israeli Prime Minister Ehud Olmert said Tuesday he was not slowing down after being diagnosed with prostate cancer, boasting about his strenuous morning exercise routine. Doctors say early detection means Olmert has a good chance of avoiding long-term damage from the disease or from his upcoming surgery. Olmert said he is pleased his case is inspiring large numbers of Israeli men to get tested. "I'm continuing my schedule on an ordinary basis. I had a very hard workout this morning," he said at a news conference. "I have no other news to share with you about this." Olmert, 62, called a news conference last week to inform the public that a biopsy following a routine medical check revealed a microscopic, non life-threatening tumor in his prostate. The prostate is a walnut-shaped gland beneath the base of the penis that produces the seminal fluid that, along with sperm, produces semen.
Focal Therapy Considered As Prostate Cancer Treatment
Gold Supplement is focused on a series of 12 peer-reviewed studies on the use of focal therapy in the treatment of prostate cancer.The studies were conducted by a group of leading urologists and radiologists led by David Bostwick, M.D., a pathologist specializing in urology, and Gary Onik, M.D., an interventional radiologist, both of whom served as co-editors of the supplement. This is the first published scientific compendium dedicated solely to focal prostate cancer treatment. One of the leading focal treatment methods is cryoablation, or the minimally invasive freezing of the cancerous tumors to destroy them.The studies presented in the supplement cover a broad range of issues related to focal therapy for prostate cancer including cancer volume; patient selection; biopsy techniques to adequately find and diagnose the extent of the cancer and the long-term effectiveness of focal treatments.In basic terms, focal therapy for prostate cancer, also known as "the male lumpectomy," is a new method of treating prostate cancer where the primary objective is to destroy the cancerous tissue in the prostate gland and avoid damaging the healthy tissue including the nerve bundles at the base of the gland that control potency and continence.
|
